Clinical Report: Oxidized mannan-MOG35-55 conjugate for MS immune modulation

Overview

The oxidized mannan-MOG35-55 conjugate (OM-MOG35-55) shows promise as a targeted immunotherapy for multiple sclerosis (MS) by modulating antigen-specific immune responses, particularly through enhancing regulatory T-cell populations and cytokine production. This approach may offer a safer alternative to current disease-modifying therapies by selectively re-educating the immune system.

Background

Multiple sclerosis (MS) is a chronic autoimmune disease characterized by autoreactive T-cell responses against myelin antigens, leading to significant neurological disability. Current disease-modifying therapies (DMTs) broadly suppress immune activity but do not restore antigen-specific tolerance and may cause adverse effects such as infections and malignancies. Antigen-specific immunotherapies like OM-MOG35-55 aim to selectively re-educate the immune system while preserving protective immunity, addressing the limitations of existing treatments.

Data Highlights

Key Findings

• OM-MOG35-55 can influence dendritic cell-mediated antigen presentation.
• It favors the expansion of CD4+PD-1+ and CD4+CD25+Foxp3+ T-cell populations.
• OM-MOG35-55 promotes the production of regulatory cytokines such as IL-10 and TGF-β1.
• Combining OM-MOG35-55 with vitamin D3 conditioning enhances its immunomodulatory potential.
• The structural integrity of myelin proteins is critical for immune recognition and modulation.

Clinical Implications

The findings suggest that OM-MOG35-55 could be developed as a personalized immunotherapy for MS, potentially reducing the risk of adverse effects associated with broad immunosuppression. Clinicians should consider the role of antigen-specific therapies in the management of MS, particularly for patients who may not respond well to conventional DMTs, and explore integration into existing treatment paradigms.

Conclusion

The oxidized mannan-MOG35-55 conjugate represents a promising avenue for antigen-specific immunotherapy in MS, warranting further clinical validation through specific trials to establish its efficacy and safety in human patients.

References

1. Acta Neuropathologica, 2015 -- Neutralization of Myelin-Associated EphrinB3 by Antibodies Enhances Remyelination in the Central Nervous System
2. Acta Neuropathologica, 2020 -- Pathological Insights into Inflammatory Demyelinating Disorders of the Central Nervous System Associated with Myelin Oligodendrocyte Glycoprotein Autoantibodies
3. Acta Neuropathologica, 2017 -- Variations in Immune Effector Mechanisms Affecting Cortical Demyelination in Multiple Sclerosis
4. Acta Neuropathologica, 2016 -- Antibodies Targeting Myelin Trigger T Cell-Driven Autoimmune Disorders in the Central Nervous System by Marking Endogenous Antigens
5. Multiple Sclerosis Journal, 2024 -- ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis
6. Subcutaneous Ocrelizumab in Patients With Multiple Sclerosis: Results of the Phase 3 OCARINA II Study - PubMed
7. Myelin Oligodendrocyte Glycoprotein (MOG)35-55 Mannan Conjugate Induces Human T-Cell Tolerance and Can Be Used as a Personalized Therapy for Multiple Sclerosis - PubMed
8. 751049 MSJ0010.1177/1352458517751049Multiple Sclerosis JournalX Montalban, R Gold
9. Subcutaneous Ocrelizumab in Patients With Multiple Sclerosis: Results of the Phase 3 OCARINA II Study - PubMed
10. Myelin Oligodendrocyte Glycoprotein (MOG)35-55 Mannan Conjugate Induces Human T-Cell Tolerance and Can Be Used as a Personalized Therapy for Multiple Sclerosis - PubMed